Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Xenofon BaraliakosAtul A DeodharDésirée Mfm van der HeijdeMarina MagreyWalter P MaksymowychTetsuya TomitaHuji XuUte MassowCarmen FleurinckAlicia M EllisThomas VauxJulie Shepherd-SmithAlexander MartenLianne S GenslerPublished in: Annals of the rheumatic diseases (2023)
NCT03928704; NCT03928743.